Health issues in the framework of Horizon 2020
Research and
Innovation
Rosanna D'Amario
Horizontal Aspects Unit
Health Directorate
Research and Innovation DGRosanna.D'[email protected]
Incontro presso la
Regione Basilicata
Bruxelles, Belgio
3 ottobre 2013
Seventh Framework Programme for Research and Technology Development (FP7, 2006-2013)
Key figures
6 b€ invested to date
First outcomes(on 281 closed projects)
200
Research and
Innovation
6 b€ invested to date
1,000 projects
11,000 participations
3,500 organisations
130 countries
200 patent applications
9,000 publications
3,3 average SJR* publication
30 spin-offs created
* SCImago Journal Ranking
• Mammography with Molecular Imaging
• Science and engineering to develop machines for breast
MAMMI project
Research and
Innovation
develop machines for breast scanning
• Improve the quality of imaging, detect cancer cells at a much earlier stage
• MAMMI prototype gives quicker follow-up information to monitor how treatment is going
• www.mammiproject.com
• Unbiased biomarkers for the prediction of respiratory disease outcomes (IMI project)
• Building up a much more detailed picture of genetic information in
U-BIOPRED project
Research and
Innovation
picture of genetic information in each individual
• 1 000 patients in order to create a unique database of biological and clinical information
• Determine an individual ‘handprint’ of asthma triggering attacks and driving disease progression
• www.ubiopred.european-lungfoundation.org
1. Excellent science
2. Industrial leadership
Horizon 2020: Three priorities
Research and
Innovation
3. Societal challenges
Horizon 2020 Content & Structure (1)
European Research Council
Frontier research by the best individual teams
Priority 1. Excellent science (~< 32%)
Research and
Innovation
Future and Emerging Technologies
Collaborative research to open new fields of innovation
Marie Curie Actions
Opportunities for training and career development
Research Infrastructures (including e-infrastructure)
Ensuring access to world-class facilities
Leadership in enabling and industrial technologies(ICT, nanotechnologies, materials, biotechnology,
Priority 2. Industrial leadership (~>22%)
Horizon 2020 Content & Structure (2)
Research and
Innovation
(ICT, nanotechnologies, materials, biotechnology,
manufacturing, space)
Access to risk finance
Leveraging private finance and venture capital for
research and innovation
Innovation in SMEs
Fostering all forms of innovation in all types of SMEs
Health, demographic change and wellbeing
Food security, sustainable agriculture, marine
Priority 3. Societal challenges (~> 38%)
Horizon 2020 Content & Structure (3)
Research and
Innovation
Food security, sustainable agriculture, marine and maritime research & the bio-economy
Secure, clean and efficient energy
Smart, green and integrated transport
Climate action, resource efficiency and raw materials
Inclusive societies
Secure societies
Spreading excellence & widening participation
Other (~< 8%)
Horizon 2020 Content & Structure (4)
Research and
Innovation
participation
Science with and for society
European Institute of Technology
Joint Research Centre
Horizon 2020 Modalities (1)• Collaborative research projects require at least three legal
entities from different EU Member States
• Activities requiring at least one legal entity
Research and
Innovation
• European Research Council
• Training & mobility action
• SME instrument
• Programme co-fund
• Coordination & support actions
• Calls for proposals open to organizations from countries outside Member States and Associated Countries
Horizon 2020 Modalities (2)
Investing in partnerships in research and innovation
• Launch of partnerships on 10 July 2013
Research and
Innovation
• 5 Public-private partnerships (proposed in form of Joint Technology Initiatives (JTIs)
• 1 Joint Undertaking
• 4 Joint Programmes with EU Member States
• All together these account for approximately 22 bn €
Timeline 2013:• Jan 2013: First Strategic Programme
• Feb 2013: First meetings of the Horizon 2020 Groups
• Jul 2013: Consultation of HLG MS representatives
• Summer 2013: Draft first work programme
Research and
Innovation
• Summer 2013: Draft first work programme
• Autumn 2013: Inter-service consultation and consultation of the Member States
• 10 Dec 2013: Adoption of the work programme and publication of the calls for proposals
• 2014: Expected deadline …
Societal Challenge Health,Demographic Change and Wellbeing (1)
• Understanding the determinants of health (including environmental and climate related factors), improving health promotion and disease prevention;
Research and
Innovation
• Developing effective screening programmes and improving the assessment of disease susceptibility
• Improving surveillance and preparedness
• Understanding disease
• Developing better preventive vaccines
• Improving diagnosis
• Using in-silico medicine for improving disease management and prediction
Societal Challenge Health,Demographic Change and Wellbeing (2)
• Treating disease
• Transferring knowledge to clinical practice and scalable innovation actions
• Better use of health data
Research and
Innovation
• Better use of health data
• Improving scientific tools and methods to support policy making and regulatory needs
• Active ageing, independent and assisted living
• Individual empowerment for self-management of health
• Promoting integrated care
• Optimising the efficiency and effectiveness of healthcare systems and reducing inequalities
Proposed Work Programme Cycle
2014 2015 2016 2017 2018 2019 2020
Strategic Programme
Research and
Innovation
Work Programme 1(plus tentative information for2016)
Strategic Programme
Work Programme 2(plus tentative information for2018)
Strategic Programme
Work Programme 3(plus tentative information for2020)
Work Programme4
Special supportfor SMEs in Horizon 2020
• ~5 billion EUR in H2020
• Inspired by the US model "SBIR"
Research and
Innovation
"SBIR"
• Challenge driven, bottom up
• A single company can be funded
• 3 phases / 3 entry points:
• Concept and feasibility assessment • R&D, demonstration, market
replication • Commercialization
A few points to remember
• 1b€/year devoted to health research in Horizon 2020
• One rule: Minimum 3 partners from 3 EU countries + anyone else from
Research and
Innovation
EU countries + anyone else from anywhere in the world
• Funding: 3-12 m€ per project 100%+25% reimbursement rate
• Project duration: 3-5 years
• Call publication: 11 December 2013
How to apply in Horizon 2020?
1. Read the call, identify a relevant topic
Research and
Innovation
2. Find relevant partners
3. Write and submit your proposal
4. Get funded (~10% success rate)!
International K.O. Mouse Consortium
International Human Microbiome Consortium
Continued international cooperation
Research and
Innovation
International Cancer Genomics Consortium
International Human Epigenome Consortium
International Rare Disease Research
Consortium
International Initiative for Traumatic Brain
Injury Research
© rtg
uest/F
oto
lia.c
om
Global Alliance for Chronic Diseases
200 New Therapies
IRDiRC vision and 2020 goals
Research and
Innovation
Means to Diagnose Most Rare Diseases
© Y
uri
Arc
urs
/Foto
lia.c
om
© n
yul/
Foto
lia.c
om
IRDiRC: 35 members
Europe
E-RARE 2 Consortium (EU)
European Commission (EU)
EURORDIS (EU)
French Muscular Dystrophy Association (FR)
French National Research Agency (FR)
German Federal Ministry of Education and research (DE)
North America
Canadian Institutes for Health Research (CA)
FDA Orphan Products Grants Program (US)
Genome Canada (CA)
Genetic Alliance (US)
Mendelian Disorders Genome Centres (US)
National Centre for Translational Sciences (US)
Asia
BGI (CN)
Chinese Rare
Research and
Innovation
and research (DE)
Istituto Superiore di Sanità (IT)
Italian Telethon Foundation (IT)
Lysogene (FR)
Netherlands Organisation for Health Research and Development
Prosensa (NL)
Spanish Carlos III Health Institute (ES)
UK National Institute for Health Research (UK)
National Cancer Institute (US)
National Institute of Neurological Disorders and Stroke (US)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (US)
National Institute of Child Health and Human Development (US)
National Eye Institute (US)
NKT Therapeutics (US)
NORD (US)
Office of Rare Diseases (US)
PTC Therapeutics (US)
Sanford Research (US)
Shire (US)
© rtg
uest/F
oto
lia.c
om
Australia
National Health and Medical Research Council
Western Australian Department of Health
Chinese Rare Disease Consortium (CN)
Korea National Institute of Health (KR)
Global Alliance for ChronicDiseases: Global health challenges
Why international cooperation ?
• Health research is a priority for all of us• Addressing global challenges needs critical mass of resources,
Research and
Innovation
• Addressing global challenges needs critical mass of resources, expertise, infrastructures, patients
• Need for data sharing, exchange of good practices• Sharing work and costs
Strategic objectives
• Tackle chronic non-communicable diseases• Contribute towards the MDGs• GACD is a unique model of pairing HIC with LMIC researchers
More @ http://www.gacd.org/
Global Research Collaboration for Infectious Disease Preparedness
Objective: to coordinate and initiate researchefforts addressing infectious epidemic within 48hours after an outbreak
Research and
Innovation
hours after an outbreak
• Launched in Brussels February 2013
• Current participating countries: Australia, Canada, China,France, UK, US, Sweden
• Interested funding bodies are invited to participate -nextmeeting 9-10 October 2013 Annecy, France
• Contact point: RTD-Unit F.3 Infectious Diseases andPublic Health, Line Matthiessen, Head of Unit
EDCTP: The European and DevelopingCountries Clinical Trials Partnership
• Established in 2003 as Part of the Union's response to the global health crisis caused by HIV/AIDS, malaria and tuberculosis
• Collaboration between the EC, 16 European countries and 48 sub-Saharan African
Research and
Innovation
countries and 48 sub-Saharan African countries
• Pioneered joint programming, i.e. the coordination, alignment and integration of European national research programmes.
• Objectives:
• Funding clinical trials on HIV/AIDS, TB and Malaria
• Strengthening related capacities
EDCTP2 - Renewal of the "European andDeveloping Countries Clinical Trials Partnership"
• Second phase of EDCTP expected to be launched early 2014 with:
a) extended scope to include neglected infectious diseases, all clinical phases, diagnostics and delivery optimization
Research and
Innovation
diagnostics and delivery optimization
b) increased budget
c) extended duration
• Political and financial up-front commitment from 17 European countries of more than €594 million
• EU will provide matching co-funding through Horizon 2020
• International partners welcomed
IMI: Innovative Medicines Initiative
• New type of public/private
partnership
• 1:1 funding, joint decision making
Research and
Innovation
• All EU funding goes to SMEs,
academia, patient organisations
and regulatory agencies
• Large pharmaceutical industry,
represented by EFPIA, contributes
in-kind
1 billion EUR 1 billion EUR
2 billion EUR
In the pipeline: IMI2
• Commission proposal published on 10 July
• Mission: create an even more powerful research and innovation machine – with broader objectives and a wider range of activities and partners
Research and
Innovation
• Proposed budget from public and private partners: 3.5 Billion Euro
• Key objectives:
• Pave the way for the breakthroughvaccines, medicines and treatmentswhich we will need in the near future
• Enable top quality research andinnovations with great public healthbenefits and commercial possibilities
Grazie dell'attenzione!
Research and
Innovation
Per ulteriori informazioni:
www.ec.europa.eu/research/horizon2020